Trials / Completed
CompletedNCT01728623
A Study of E7080 in Subjects With Advanced Thyroid Cancer
A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally administered once daily (QD) in subjects with advanced thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7080 capsule | E7080 is administered as continuous once daily dosing in an uncontrolled manner |
Timeline
- Start date
- 2012-09-03
- Primary completion
- 2015-07-09
- Completion
- 2015-10-01
- First posted
- 2012-11-20
- Last updated
- 2020-08-14
- Results posted
- 2020-08-14
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01728623. Inclusion in this directory is not an endorsement.